SynthesisClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2026
Comparison of PD-L1 expression between biopsy specimens and surgical resection specimens in non-small cell lung cancer: a meta-analysis.
Synthesis in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionWhether programmed cell death ligand 1 (PD-L1) expression differs between different specimen types remains unclear. This meta-analysis aimed to compare PD-L1 expression between biopsy and surgical specimens in non-small cell lung cancer (NSCLC).
methodsWe searched the PubMed and Web of Science databases from January 2015 to December 2025 to evaluate PD-L1 expression detection across different types of specimens. The QUADAS-2 tool was used to evaluate the quality of the included studies. Review Manager 5.4 and Stata 17.0 were used to calculate the relative risk (RR) and the corresponding 95% confidence interval (95% CI).
resultsThis meta-analysis of 13 studies involving 966 patients demonstrated that no significant difference in PD-L1 positivity rates between biopsy and surgical specimens was observed at the 1% cutoff (RR = 0.85, 95% CI [0.71 - 1.01], P = 0.07), but a significant difference was detected at the 50% cutoff (RR = 0.76, 95% CI [0.65 - 0.90], P < 0.01). Similar findings were observed in patients without neoadjuvant therapy. Additionally, PD-L1 expression in tumor cells was significantly lower with the SP142 assay than with other antibodies at both the 1 and 50% cutoffs.
conclusionsPD-L1 expression may differ between biopsy specimens and surgically resected specimens in patients with advanced NSCLC, even in patients who have not received neoadjuvant therapy. Consequently, PD‑L1 status evaluated from biopsy specimens should be interpreted with caution in clinical practice. In addition, the selection of PD-L1 immunohistochemistry (IHC) detection methods may also affect the evaluation results.
Indexed as
Identifiers
42177725What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.